Radish Systems is awarded a patent for its integrated voice/data technology

Tuesday, April 18, 2017

BOULDER, CO (April 18, 2017) – Radish Systems, a leader in voice and data mobility solutions for visual customer service, announces that it has been awarded a second key patent from the U.S. Patent and Trademark Office for its integrated voice/data technology known in the market as ChoiceView®. This patent, which dates from 2009, significantly extends the reach of Radish's intellectual property from an environment of mobile apps and Windows software to an environment of web apps and websites. ChoiceView marries telephone and Internet technology for rich 'voice with visuals' calls. U.S. patent # 9,521,259 covers most any conceivable way for users to engage in voice-and-visual calls with businesses, even though they may not use a smartphone, have a pre-installed app, or expect anything other than a voice-only call. It also covers new system configurations for businesses resulting in even faster deployment and easier integration of next generation, multi-modal business communications through many channels which solve real problems -- irritated customers tired of voice-only Interactive Voice Response (IVR) systems, repeating information, long hold and processing times, and lack of self-service. ChoiceView is available now to license direct for business use and for other communications firms to easily embed 'voice with visuals' capabilities in their systems. 

Nivalis Therapeutics acquired by Seattle-based Alpine Immune Systems

Tuesday, April 18, 2017

A Seattle biotech company is acquiring Boulder’s Nivalis Therapeutics, merging with it to become publicly traded and use Nivalis’ $44 million in cash to fund new immunotherapy cancer and inflammatory disease treatments. 

CereScan's Latest Patent for its Neuroimaging Database Now Covers All Brain Activity Measurement Methods

Tuesday, April 11, 2017

In response to an application filed with the United States Patent and Trademark Office, CereScan® has broadened the parameters on its automated diagnostic assistance and intelligent support system, CereMetrix®, which uses quantitative measurements to assist in the diagnosis and study of complex brain disorders. Through award of a second patent, the company may now claim exclusive use of its neuroimaging database systems and methods in the measurement of all types of brain activity. The patent expands CereScan’s intellectual property and use of its wholly owned data warehouse, known to be the most comprehensive store of functional brain imaging data, associated patient demographic, clinical information and biomarkers worldwide. 

Biodesix Presents Data From Three Studies at AACR Annual Meeting

Wednesday, April 05, 2017

New data on liquid biopsy genomic tests, including multiplexed genomic assays; evaluation of biological processes underlying mass spectrometry proteomic assays of human serum. 

SomaLogic announces the appointment of long-time Board member Alister W. Reynolds as Chief Executive Officer

Wednesday, April 05, 2017

Former CEO Byron Hewett steps down after successfully building the foundation for SomaLogic’s future growth. 

ArcherDX announces strategic partnership with Chinese firm HeliTec for NGS-based diagnostic development

Tuesday, April 04, 2017

ArcherDX, the leader in NGS-based oncology sequencing applications, and the precision medicine company HeliTec announced today a strategic partnership to advance NGS-based cancer diagnostic development in China. The partnership will entail co-developing and cross-licensing NGS-based technologies with the goal of registering oncology diagnostic kits with the Chinese Food and Drug Administration (CFDA). 

InDevR Collaborates with I&L Biosystems to Market Products in Western Europe

Tuesday, April 04, 2017

BOULDER, Colo.--(BUSINESS WIRE)--InDevR, Inc., an innovative life science company dedicated to improving biopharmaceutical and vaccine manufacturing, is pleased to announce an exclusive sales, marketing and customer support relationship with I&L Biosystems GmbH and its subsidiaries. The distribution agreement includes sales and support for the Cypher One™ and soon to launch VaxArray™ product lines throughout Western Europe. 

New Data Show Biodesix’s VeriStrat® Test is Cost-Saving, Improves Survival and Quality of Life in Advanced Lung-Cancer Patients

Monday, April 03, 2017

BOULDER, Colo., April 03, 2017 (GLOBE NEWSWIRE) -- Biodesix®, Inc. announced today new data demonstrating that use of the VeriStrat® test in patients with advanced non-small cell lung cancer (NSCLC) reduces the aggregate costs of end-of-life treatment while improving survival and quality of life. The data were presented at the American College of Medical Quality (MQ2017) annual meeting, which was held March 29 - April 1 in Washington, DC. 

VetDC Announces Commercial Launch of TANOVEA™-CA1 for Lymphoma in Dogs

Monday, April 03, 2017

FORT COLLINS, Colo.--(BUSINESS WIRE)--VetDC, Inc., a veterinary cancer therapeutics company, today announced that TANOVEA™-CA1 (rabacfosadine for injection) is now commercially available in the US for purchase by licensed veterinarians. TANOVEA-CA1 was recently granted conditional approval by the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM), making TANOVEA-CA1 the first and only new animal drug indicated for the treatment of lymphoma in dogs.